Keeping Track, Oncology Edition: Biologic Breakthroughs And BLAs
The latest oncology development news and highlights from our US FDA Performance Tracker.
You may also be interested in...
Keeping Track: US FDA Receives Advanced Biologic BLAs From ImmunityBio, CSL; Nymox, Medac Stumble
The latest NDA and BLA submission news and highlights from the Pink Sheet’s US FDA Performance Tracker
Endpoint Milestone In AML: Kronos’ Entospletinib Trial Will Rely On Residual Disease
Phase III study in newly diagnosed patients with NPM1-mutated AML could enable Kronos’ SYK-inhibitor to reach market two years earlier under accelerated approval than it would under a traditional endpoint, company says.
Keeping Track: Oncology Submissions From Blueprint, Y-mAbs, BMS/bluebird; Approvals For BMS’ Reblozyl, LFB’s SevenFact
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.